Sandy Spring Bank’s Humacyte HUMA Stock Holding History

Sandy Spring Bank’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,335	Closed	-$15K	–	1230
2021 Q3	$15K	Buy	+1,335	New	+$15.3K	﹤0.01%	807

Other funds holding HUMA

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

DCP

Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sandy Spring Bank's HUMA Position: Q4 2021 in Review

Sandy Spring Bank sold out of Humacyte (HUMA) in Q4 2021, closing a stake of 1,335 shares — an estimated $15K sold.

Sandy Spring Bank first reported a position in HUMA in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 61 funds tracked by Wall St. Rank hold HUMA as of Q4 2021.

Sandy Spring Bank reported no remaining Humacyte position as of Q4 2021 after selling out during the quarter.
Sandy Spring Bank sold 1,335 Humacyte shares in Q4 2021, an estimated $15K.
Sandy Spring Bank first reported a position in Humacyte in Q3 2021 and held it in 1 quarter.
Sandy Spring Bank's Humacyte position peaked at $15K in Q3 2021.
61 funds tracked by Wall St. Rank held Humacyte as of Q4 2021.

Based on Sandy Spring Bank's 13F filing for Q4 2021, filed 11 Feb 2022.